Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor.本文揭示用於治療B細胞惡性病之方法、組成物、及套組,其包括投予BTK抑制劑(例如,依魯替尼(Ibrutinib))與PIM抑制劑之組合。本文亦揭示用於治療BTK抗性B細胞惡性病之方法、組成物、及套組,其包括投予BTK抑制劑(例如,依魯替尼)與PIM抑制劑之組合。